Europe builds trust in risk/benefit studies
A new form of study for assessing the benefits and risks of medicines has been launched in the EU with the hope of increasing public trust in study findings.
A new form of study for assessing the benefits and risks of medicines has been launched in the EU with the hope of increasing public trust in study findings. Investigators who choose to conduct the new type of study commit to a “maximum level of transparency”, according to a statement from the European Medicines Agency (EMA), which includes the publication of all study findings — whether positive or negative. Relevant information will also be entered into a publicly available electronic register (currently being developed by the EMA) before the study commences.
The initiative is being led by the EMA and the European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP). The studies will be called ‘ENCePP studies’ and will act as a seal that the EMA hopes will “increase trust in the robustness of findings”.
ENCePP benefit/risk or risk studies will be performed in compliance with the ENCePP’s code of conduct, which is designed to ensure transparency and promote scientific independence. The code lays down rights and obligations between investigators and study funders, and covers aspects such as the development of the study protocol, the conduct of the study and data ownership, as well as access to data and publication of the results.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
